The FASEB Journal, Vol 10, 1303-1309, Copyright © 1996 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir

A Zarain-Herzberg, H Rupp, V Elimban and NS Dhalla
Division of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Manitoba, Canada.

Pressure overload on the heart is known to produce hypertrophy of cardiomyocytes and distinct changes in protein phenotype, including reduced expression of the gene for the sarcoplasmic reticulum (SR) Ca2+ATPase (SERCA2). In this study we have shown that the decrease in SERCA2 gene expression (normalized by poly(A)+ mRNA or 18 S rRNA) in rats with 8 wk of aortic constriction was prevented by treatment with etomoxir, an inhibitor of carnitine palmitoyltransferase 1. The reduction in steady-state mRNA levels for SR phospholamban (PLP) and Ca2+ release channel (CRC) in the pressure-overloaded animals was also prevented without any reduction in the extent of cardiac hypertrophy by treatment with etomoxir. Although no changes in mRNA levels for GAPDH were evident in rats with pressure overload, the expression of the alpha-skeletal actin was increased; this change was prevented by etomoxir. Similar beneficial effects of etomoxir treatment were also evident when the gene expression for SR SERCA2, PLP, and CRC in the hypertrophied heart was normalized with respect to mRNA for GAPDH. These results support the view that drugs such as etomoxir may increase the abundance of the mRNA for SR proteins in the hypertrophied heart and thus may prevent the transition of cardiac hypertrophy into heart failure.

This article has been cited by other articles:

				N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45. [Abstract] [PDF]

				W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]

				M. E. Young, P. McNulty, and H. Taegtmeyer Adaptation and Maladaptation of the Heart in Diabetes: Part II: Potential Mechanisms Circulation, April 16, 2002; 105(15): 1861 - 1870. [Full Text] [PDF]

				U Ravens and D Dobrev Regulation of sarcoplasmic reticulum Ca2+-ATPase and phospholamban in the failing and nonfailing heart Cardiovasc Res, January 1, 2000; 45(1): 245 - 252. [Full Text] [PDF]

				N. S. DHALLA, L. GOLFMAN, X. LIU, H. SASAKI, V. ELIMBAN, and H. RUPP Subcellular Remodeling and Heart Dysfunction in Cardiac Hypertrophy due to Pressure Overload Ann. N.Y. Acad. Sci., June 30, 1999; 874(1): 100 - 110. [Abstract] [Full Text] [PDF]

				O. Zolk, M. Flesch, G. Nickenig, P. Schnabel, and M. Bohm Alteration of intracellular Ca2+-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats Cardiovasc Res, July 1, 1998; 39(1): 242 - 256. [Abstract] [Full Text] [PDF]

				J. T. Thompson, M. S. Rackley, and T. X. O'Brien Upregulation of the cardiac homeobox gene Nkx2-5 (CSX) in feline right ventricular pressure overload Am J Physiol Heart Circ Physiol, May 1, 1998; 274(5): H1569 - H1573. [Abstract] [Full Text] [PDF]

				M. A Movsesian and R. H.G Schwinger Calcium sequestration by the sarcoplasmic reticulum in heart failure Cardiovasc Res, February 1, 1998; 37(2): 352 - 359. [Full Text] [PDF]

				M. Turcani and H. Rupp Etomoxir Improves Left Ventricular Performance of Pressure-Overloaded Rat Heart Circulation, November 18, 1997; 96(10): 3681 - 3686. [Abstract] [Full Text]